Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.

Stages of Non-Small Cell Lung Cancer Once a person has been diagnosed with cancer, their healthcare team conducts additional tests to determine the cancer stage. The stage describes how advanced ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Approximately 80% of individuals who receive immune checkpoint inhibitors for advanced cancer do not respond to therapy, according to results of a cross-sectional analysis.The number of FDA-approved ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, has published a peer-reviewed study highlighting a potential breakt ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...